Stocks
KalVista Pharmaceuticals, Inc.KALV
NASDAQHealthcareBiotechnology$16.94-2.53%
Focused on the discovery and development of small molecule protease inhibitors, this biopharmaceutical company targets treatments for hereditary angioedema and diabetic macular edema. Its pipeline includes oral therapies that could address unmet medical needs, making it a key player in the rare disease and ophthalmology markets.
Market Cap: $856.3M52W Range: $9.23 – $19.00
Congressional Interest in KalVista Pharmaceuticals, Inc. (KALV)
1 member of Congress has disclosed 1 trade in KalVista Pharmaceuticals, Inc. (KALV), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading KALV?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |